PARP Inhibitor Inhibits the Vasculogenic Mimicry through a NF-κB-PTX3 Axis Signaling in Breast Cancer Cells

Poly (ADP-ribose) polymerase inhibitors (PARPi) are targeted therapies that inhibit PARP proteins which are involved in a variety of cell functions. PARPi may act as modulators of angiogenesis; however, the relationship between PARPi and the vasculogenic mimicry (VM) in breast cancer remains unclear...

Descripción completa

Detalles Bibliográficos
Autores principales: Chivot, Justine, Ferrand, Nathalie, Fert, Aude, Van Dreden, Patrick, Morichon, Romain, Sabbah, Michèle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9785325/
https://www.ncbi.nlm.nih.gov/pubmed/36555812
http://dx.doi.org/10.3390/ijms232416171

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9785325/
https://www.ncbi.nlm.nih.gov/pubmed/36555812
http://dx.doi.org/10.3390/ijms232416171

Ejemplares similares